Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Inclusion Criteria: * Ability to understand character and individual consequences of the clinical trial. Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial; * Aged ≥ 18 years old; * Pathologically confirmed inoperable or iodine refractory thyroid cancer, or postoperative residual disease detected by imaging studies, or progression disease within 12 months before enrollment. (all with measurable disease ≥10mm according to RECIST 1.1); * ECOG0-2; * Adequate laboratory values within 14 dyas of enrollment to study defined as follows: N ≥ 1500/mm\^3; PLT ≥ 80,000/mm\^3; HB≥90g/L;total bilirubin \< 1.25ULN; AST/ALT \< 2.5 ULN or \< 5 ULN with metastasis; SCr ≤1ULN; CCR \> 50ml/min; * The survival period is expected to be greater than 3 months; * Willing to accept adequate contraception for patients with childbearing potential. Exclusion Criteria: * Take chemotherapeutic chemotherapy (the use of low-dose chemotherapy for radiosensitization was allowed) or thalidomide and its derivative treatments; * Take VEGFR-TKI within 1 month, such as vandetanib, cabozantinib, lenvatinib, sunitinib and sorafenib; * Allergic to apainib; * Uncontrolled high blood pressure and heart disease; * Patients with gastrointestinal bleeding risk; * Coagulation disorders(INR\>1.5×ULNAPTT\>1.5×ULN); * Uroprotein positive (Uroprotein≥2+ or 24-hour urinary protein quantity \>1.0g); * Pregnant or lactating women.